Effect of time of administration on the pharmacokinetics and tolerance of doxazosin in healthy male volunteers

Journal of Clinical Pharmacology

Volumn 36, Issue 4, 1996, Pages 325-331

  Vashi, Vijay ^a   Chung, Menger ^a   Dias, Norma ^a   Phillips, Kem ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXAZOSIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG TOLERABILITY; HUMAN; HUMAN EXPERIMENT; HYPOTENSION; MALE; NOCTURIA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL; TIME; VOLUNTEER;

EID: 0029916511     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04208.x     Document Type: Article

References (17)

1. Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure: The Fifth Report of the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure (JNC-V). Arch Intern Med 1993;153:154-183.
2. Kaye B, Cussans NJ, Faulkner JK, Stopher DA, Reid JL: The metabolism and kinetics of doxazosin in man, mouse, rat and dog. Br J Clin Pharmacol 1986;21(suppl):19S-25S.
3. Frick MH, Halttunen P, Himanen P, Huttunen M, Pörsti P, Pitkäjärvi T, et al: A long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertension. Br J Clin Pharmacol 1986;21(suppl):55S-62S.
4. Carlson RV, Bailey RR, Begg EJ, Cowlishaw MG, Sharman JR: Pharmacokinetics and effect on blood pressure of doxazosin in normal subjects and patients with renal failure. Clin Pharmacol Ther 1986;40:561-566.
5. Elliott HL, Meredith PA, Vincent J, Reid JL: Clinical pharmacology studies with doxazosin. Br J Clin Pharmacol 1986;21(suppl): 27S-31S.
6. Vincent J, Meredith PA, Elliott HL, Reid JL: The pharmacokinetics of doxazosin in elderly normotensives. Br J Clin Pharmacol 1986;21:521-524.
7. Vincent J, Elliott HL, Meredith PA, Reid JL: Doxazosin, an alpha1 adrenoceptor antagonist: pharmacokinetics and concentration-effect relationships in man. Br J Clin Pharmacol 1983;15:719-725.
8. Cubeddu LX, Fuenmayor N, Caplan N, Ferry D: Clinical pharmacology of doxazosin in patients with essential hypertension Clin Pharmacol Ther 1987;41:439-449.
9. Conway EL, McNeil JJ, Hurley J, Jackman GP, Krum H, Howes LG, Louis WJ: The effects of food on the oral bioavailability of Doxazosin in hypertensive subjects. Drug Invest 1993;6:90-95.
10. Rubin PC, Brunton J, Meredith P: Determination of the vasodilator UK33274 by high-performance liquid chromatography using fluorescence detection. J Chromatogr B Biomed Appl 1980;221: 193-195.
11. Chung M, Leitz FH, Maier G, Patrik JE, Gural RP, Symchowicz S: Rising multiple-dose pharmacokinetics of labetalol in hypertensive patients. J Clin Pharmacol 1986;26:248-252.
12. Schuirmann DJ: A comparison of the two one sided tests procedure and the power approach for assessing the equivalence of the average bioavailability. J Pharmacokinet Biopharm 1980;15: 657-680.
13. Conway EL, McNeil JJ, Meng L: Single-dose and steady-state pharmacokinetics of doxazosin given in combination with chlorothiazide to hypertensive subjects. Clin Pharmacokinet 1989;16: 387-391.
14. Elliott HL, Meredith PA, Sumner DJ, McLean K, Reid JL: A pharmacodynamic and pharmacokinetic assessment of a new α-adrenoceptor antagonist, doxazosin (UK33274), in normotensive subjects. Br J Clin Pharmacol 1982;13:699-703.
15. Levy G: Effect of bedrest on the distribution and elimination of drugs. J Pharm Sci 1967;56:928-929.
16. Roberts MS, Denton MJ: Effect of posture and sleep on pharmacokinetics. Eur J Clin Pharmacol 1980;18:175-183.
17. Scott PJW, Hosie J, Scott MGB: A double-blind and cross-over comparison of once daily doxazosin and placebo with steady-state pharmacokinetics in elderly hypertensive patients. Eur J Clin Pharmacol 1988;34:119-123.